European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Approval supported by data from one of the largest registrational Phase 3 programs in atopic dermatitis evaluating RINVOQ (upadacitinib) monotherapy or with topical corticosteroids[1]
RINVOQ met all primary and secondary endpoints, demonstrating rapid a... Biopharmaceuticals, Dermatology, Regulatory AbbVie, RINVOQ, upadacitinib, atopic dermatitis, JAK inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 24, 2021 Category: Pharmaceuticals Source Type: news
Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks
The JAK inhibitor shows efficacy and safety when used in combination with topical corticosteroids, and showed superiority in a head-to-head comparison with dupilumab.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 19, 2021 Category: Dermatology Tags: Allergy & Clinical Immunology News Source Type: news
Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [<80 kg] / 1400 mg [≥80 kg]).[1] These findings will be featured at th...
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Continuous Corticosteroids Best for Mild, Well-Controlled, Asthma? Continuous Corticosteroids Best for Mild, Well-Controlled, Asthma?
Discontinuing ICS may make sense for some patients with well-controlled asthma, but some patients with mild and well-controlled disease may fare better by continuing treatment, according to a study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2021 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 10th August 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily.
We are continually monitoring the evidence and updating the guideline as new information emerges. Priority areas for update include recommendations on heparins.
On 10 August 2021, we corrected an error in the practical info section of the recommendations on corticosteroids. The dose of prednisolone for c...
Source: Current Awareness Service for Health (CASH) - August 12, 2021 Category: Consumer Health News Source Type: news
Sjogren's Syndrome With Nervous System Injury and Cryptococcosis Sjogren's Syndrome With Nervous System Injury and Cryptococcosis
This case details a rare form of neural involvement in Sjogren ' s syndrome, combined with pulmonary and osseous cryptococcosis due to long-term use of high-dose corticosteroids and immunosuppressants.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Waiting 3 Months After Corticosteroid Injections for TKA Waiting 3 Months After Corticosteroid Injections for TKA
When is it safe to administer corticosteroid injections in TKA patients? A new study aims to determine the optimal timing.Journal of the American Academy of Orthopaedic Surgeons (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 11, 2021 Category: Surgery Tags: Orthopaedics Journal Article Source Type: news
Are corticosteroids given orally or by injection an effective treatment for people with COVID-19?
Are corticosteroids (anti-inflammatory medicines) given orally or by injection an effective treatment for people with COVID-19?Key messagesCorticosteroids (anti-inflammatory medicines) given orally or by injection (systemic) are probably effective treatments for people hospitalised with COVID-19. The authors don’t know whether they cause unwanted effects. The authorsdon ’t know which systemic corticosteroid is the most effective. They found no evidence about people without symptoms or with mild COVID-19 who were not hospitalised. They found 42 ongoing studies and 16 completed studies that have not published thei...
Source: Cochrane News and Events - August 10, 2021 Category: Information Technology Authors: Katie Abbotts Source Type: news
Short-Acting Beta Agonist Overuse'a Global Public Health Issue'Short-Acting Beta Agonist Overuse'a Global Public Health Issue '
Overreliance on SABAs and underuse of inhaled corticosteroids are associated with increased risk of exacerbations and asthma-related death.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 12, 2021 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
SLE Neuropsych Event Etiology Helps Define Predictors, Outcomes SLE Neuropsych Event Etiology Helps Define Predictors, Outcomes
Male sex, active systemic lupus erythematosus, and corticosteroid use were among the factors positively associated with neuropsychiatric events in patients with SLE.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 10, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients
Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids. (Source: University of Bristol news)
Source: University of Bristol news - July 6, 2021 Category: Universities & Medical Training Tags: Alumni, Health, International, Postgraduate, Public engagement, Publications, Research; Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news
Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients
(King's College London) Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2021 Category: International Medicine & Public Health Source Type: news
Medical costs higher for RA patients receiving corticosteroids and those with DM in Japan
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news
Roche's Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). (Source: World Pharma News)
Source: World Pharma News - June 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
